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Patients with mucinous colorectal cancer generally have worse prognoses than those with the nonmucinous variety. The reason for
this disparity is unclear, but may result from a differential response to adjuvant chemotherapy. We examined known molecular
markers for response to common chemotherapy in these two histological subtypes. In all, 21 patients with mucinous and 30 with
nonmucinous Dukes C colorectal cancer were reviewed for demographic data and outcome. Total RNA from the tumours and
adjacent normal mucosa was isolated and reverse transcribed. Quantitative expression levels of drug pathway genes were
determined using TaqMan RT–PCR (5-fluorouracil (5-FU): TYMS, DPYD, ECGF1; oxaliplatin: GSTP1 (glutathione S-transferase pi),
ERCC1 and 2; irinotecan: ABCB1, ABCG2, CYP3A4, UGT1A1, CES2, TOP1). Mucinous tumours significantly overexpressed both TYMS
and GSTP1 relative to nonmucinous tumours and patient-matched normal mucosa. No significant differences in expression of the
remaining markers were found. Mean follow-up was 20 months; 17 patients had recurrent disease. Among patients receiving 5-FU,
those with mucinous tumours experienced shorter disease-free survival (DFS) than those with nonmucinous tumours (median DFS
13.8 vs 46.5 months, P¼0.053). Mucinous colorectal cancer overexpresses markers of resistance to 5-FU and oxaliplatin. Likewise,
DFS may be decreased in patients with mucinous tumours who receive 5-FU. The presence of mucin should be carefully evaluated in
developmental trials of new agents for treating colorectal cancer.
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Most evidence suggests that colorectal adenocarcinomas that
produce an abundance of the glycoprotein mucin portend a worse
clinical prognosis (Umpleby et al, 1985; Green et al, 1993; Nozoe
et al, 2000), although this finding has not been consistently
established (Sasaki et al, 1987; Halvorsen and Seim, 1988).
Comprising between 10 and 15% of all colorectal adenocarcino-
mas, these tumours have a mucin content of at least 60% of
tumour volume, typically at the advancing edge. The reasons for
the worse prognosis with mucinous tumours are not clear, but
possibly include difficulty obtaining complete resections (Umpleby
et al, 1985), propensity for early spread to regional lymph nodes
(Nozoe et al, 2000), and detection at more advanced stages of
disease (Halvorsen and Seim, 1988). There also may be a higher
proportion of mucinous tumours in familial cancer syndromes;
approximately 30% of mucinous tumours demonstrate micro-
satellite instability, a defining trait of hereditary nonpolyposis
colorectal cancer (Kakar et al, 2004). The responsiveness to
adjuvant chemotherapy of mucinous adenocarcinoma specifically
has not been examined.
Various genes are known to influence tumour response or
patient survival following chemotherapy (McLeod and Murray,
1999). Their products consist of intracellular drug targets, cell-
membrane transporters, components that detoxify or metabolise,
and DNA repair enzymes. TYMS encodes thymidylate synthase, a
key enzyme in pyrimidine metabolism. Numerous studies have
demonstrated that overexpression of TYMS correlates with poor
response to 5-fluorouracil (5-FU) (Johnston et al, 1995; Leichman
et al, 1997; Salonga et al, 2000; Iacopetta et al, 2001; Kornmann
et al, 2002). Likewise, elevated levels of other enzymes in the 5-FU
pathway (namely, DPYD (dihydropyrimidine dehydrogenase) and
ECGF1 (thymidine phosphorylase)) have been shown to affect
epithelial tumour sensitivity (Etienne et al, 1995; Nita et al, 1998),
clinical response (Metzger et al, 1998a), and time to recurrence
(Salonga et al, 2000) following treatment with 5-FU. Additionally,
expression levels of DPYD and ECGF1 appear to be coregulated,
particularly in metastatic colorectal cancer (Collie-Duguid et al,
2001).
Platinum agents such as oxaliplatin rely on the inability of
nucleotide excision repair genes within the tumour to successfully
remove bulky DNA adducts. Polymorphisms in ERCC1 (excision
repair crosscomplementing isoform 1) have been related to
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sdecreased survival in patients with colorectal cancer (Park et al,
2001). Similarly, expression of ERCC2 (excision repair cross-
complementing isoform 2) in gastric cancers predicts response and
survival (Metzger et al, 1998b). GSTP1 (glutathione S-transferase
pi) is a major route of detoxification of platinum agents. It is
highly overexpressed in colon cancer, and drug-resistant tumours
have elevated levels (Stoehlmacher et al, 2002).
Irinotecan is bioactivated to a more potent form via CES2
(carboxylesterase 2), and colorectal adenocarcinomas overexpres-
sing CES2 are more sensitive to the drug (Wu et al, 2002).
Irinotecan causes double-strand DNA breaks by binding to
topoisomerase-I (TOP1) (Xu and Villalona-Calero, 2002), making
it a key intracellular target. Members of the ATP-binding cassette
superfamily of proteins (ABCB1 (Patel and Mitra, 2001; Gottesman
et al, 2002) and ABCG2 (Wierdl et al, 2003)) function to export
irinotecan from tumour cells, while drug metabolism via the
cytochrome P450 system (CYP3A4 (Kehrer et al, 2002; Xu and
Villalona-Calero, 2002)) or glucuronidation (UGT1A1 (Iyer et al,
1999, 2002)) can also occur.
In the current study, we examined expression of the above 12
genes in colorectal cancer in order to characterise possible
differences in response between the mucinous and nonmucinous
subtypes of colorectal cancer. These genes were selected as likely
candidates affecting clinical response to common adjuvant
chemotherapy (i.e. 5-FU, irinotecan, and oxaliplatin) administered
following resection of locally advanced tumours. A secondary goal
was to correlate gene expression with disease-free survival (DFS),
in the context of histological subtype.
MATERIALS AND METHODS
In all, 51 Dukes stage C colorectal cancer specimens were selected
from the Tissue Procurement Core of the Siteman Cancer Center,
Washington University, St Louis, MO, USA for genetic evaluation.
No tumours from patients with known inflammatory bowel disease
or familial cancer syndromes (familial adenomatous polyposis or
hereditary nonpolyposis colon cancer) were included. In total, 21
mucinous adenocarcinomas were selected, histologically defined
by a mucin content exceeding 60% of the total tumour volume. The
remaining 30 nonmucinous tumours were randomly chosen from a
contemporary selection of 145 available Dukes’ C colorectal cancer
specimens. Adjacent normal mucosa was available for all tumours
for comparison with the malignant epithelial component. Tissue
was snap-frozen in liquid nitrogen immediately following surgical
resection and stored at  801C. Macrodissection was performed on
all tumour specimens to ensure high tumour cellularity (median
86.3%, 65–95%). Clinical data were extracted from patients’
medical records and clinic charts. The median clinical follow-up
was 17.2 months (mean 20, range 2–59 months). Six patients with
rectal cancer received neoadjuvant external beam radiation (total
dose range 2000–4500cGy). Patients gave informed consent for
tumour banking, collection of clinical information, and subsequent
decoded genetic analysis, as approved by the Washington
University Human Studies Committee and the Siteman Cancer
Center Protocol Review and Monitoring Committee.
Total RNA was extracted from the specimens using the
Stratagene MicroRNA Isolation kit (Stratagene, La Jolla, CA,
USA), and RNA was quantified with spectrophotometry. Reverse
transcription to cDNA was performed using StrataScript reverse
transcriptase with RNase Block Ribonuclease Inhibitor (Strata-
gene) and Oligo(dT) primers. TaqMan real-time PCR was
performed on the ABI Prism 7900 Sequence Detector System
(ABI, Foster City, CA, USA) with gene-specific dual-fluorescence-
labelled oligonucleotide probes (Table 1). Each reaction well
contained 10ng cDNA, JumpStart Taq ReadyMix 2  (5ml, Sigma-
Aldrich, St Louis, MO, USA), forward and reverse primers 10mM
(0.5ml each), fluorescence-labelled oligonucleotide 5mM (0.4ml),
ROX passive reference dye 100  (0.1ml), and molecular-grade
water for a total reaction volume of 10ml. RT–PCR was performed
with the following parameters: 501C for 2min to activate UNG
enzyme, 951C for 10min to denature UNG and activate DNA
polymerase, 40 cycles at 951C for 20s and 601C for 1min. All
specimen reactions were performed in triplicate with appropriate
nontemplate controls, and the coefficient of variation (CV) was
less than 5% for all replicates.
Relative gene expression was calculated using a modified
comparative threshold cycle (CT) method, as described previously
(Pfaffl, 2001; Yu et al, 2003). This method accounts for varying
RT–PCR amplification efficiencies between different primer/probe
sets, rather than assuming all genes of interest amplify at an equal
rate. Amplification efficiency (E) was determined from standard
dilution curves for each primer/probe set. b-actin was used as the
internal reference gene, as it had no significant variation between
tumour and normal samples, and less than three-fold variation
among all samples. Expression is given as a unit-less measure
relative to the calibrator specimen that had the highest CT (i.e. the
1  sample), using the following equation:
Expression ¼
E
DCTðcalibrator sampleÞ
target
E
DCTðcalibrator referenceÞ
reference
All statistical analyses were performed with GraphPad InStat
(GraphPad Software, San Diego, CA, USA). The Mann–Whitney
Table 1 TaqMan real-time PCR primers and probes
Gene (NCBI
LocusLink ID) Sequence
Reporter
dye
ABCB1 (5243) GCTGGCACAGAAAGGCATCT
CAGAGTTCACTGGCGCTTTG
TCCAGCCTGGACACTGACCATTGAAA TET
ABCG2 (9429) CAGGTCTGTTGGTCAATCTCACA
CATATCGTGGAATGCTGAAGTACTG
CCATTGCATCTTGGCTGTCATGGC TET
CES2 (8824) AATCCCAGCTATTGGGAAGGA
CTGGCTGGTCGGTCTCAAAC
TGGCCTCAAGCCATCCTCCCATCT TET
CYP3A4 (1576) TCTCCTTTCATATTTCTGGGAGACA
GCATCGAGACAGTTGGGTGTT
TGTTTCCCTACACCTCTTGCATTCCATCCT TET
DPYD (1806) ATCTTGAATCGTTGGATCTAGATCGA
GAGTAGTAGCTAGTCGCTACTGAT
ACCGTACTCATCGTAGCTACCATGAA TET
ECGF1 (1890) GGTTCCTGCGGACGGAAT
GAGTAGTAGCTAGTCGCTACTGAT
CAGCCAGAGATGTGACAGCCACCG TET
ERCC1 (2067) TACCCCTCGACGAGGATGAG
CAGTGGGAAGGCTCTGTGTAGA
CCTGGAGTGGCCAAGCCCTTATTCC TET
ERCC2 (2068) TTGGCGTCCCCTACGTCTAC
CTGGTCCCGCAGGTATTCC
CACAGAGCCGCATTCTCAAGGCG FAM
GSTP1 (2950) CCTCACCCTGTACCAGTCCAATA
TCCTGCTGGTCCTTCCCATA
TCACCTTGGGCCGCACCCTTG TET
TOP1 (7150) GGCGAGTGAATCTAAGGATAATGAA
TGGATATCTTAAAGGGTACAGCGAA
ACCATTTTCCCATCATCCTTTGTTCTGAGC TET
TYMS (7298) GCCTCGGTGTGCCTTTCA
CGTGATGTGCGCAATCATG
CATCGCCAGCTACGCCCTGCTC TET
UGT1A1 (7361) TTGGGAGTGCGGGATTCA
AGATAAGATTAAAACTGCCATTTGCA
TGGTCCCACCGCTGCCCCTA TET
Sequences are listed as forward, reverse, and probe oligonucleotides, in the 50 to 30
direction.
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sand Fisher’s exact tests were utilised as appropriate. Comparisons
between tumour samples and patient-matched normal mucosa
were made using the Wilcoxon test for matched pairs. Survival
curves were generated using the Kaplan–Meier method, with
significance assessed by the log-rank test. A P-value less than 0.05
was considered significant. Values are expressed as mean [ 95%
confidence interval (CI), þ95% CI].
RESULTS
Patient characteristics are depicted in Table 2. All patients
underwent resection with curative intent. As previously men-
tioned, all patients had positive lymph node metastases (AJCC
stage III). There were no significant differences between the
mucinous and nonmucinous groups for age at diagnosis, gender,
tumour size, histologic grade, or number of positive lymph nodes.
No mucinous tumours occurred in the rectum, whereas 20% of the
nonmucinous tumours were rectal. However, differences in
tumour location did not reach statistical significance. A total of
13 mucinous tumours occurred proximal to the splenic flexure,
compared to 14 nonmucinous tumours (P¼0.58).
Relative gene expression of DPYD, ECGF1, ERCC1, ERCC2,
ABCB1, ABCG2, CYP3A4, UGT1A1, CES2, and TOP1 did not differ
significantly between mucinous and nonmucinous tumours,
although the difference in ERCC2 expression approached statistical
significance (P¼0.083), with higher expression in the mucinous
subgroup. However, as depicted in Figure 1, TYMS expression was
significantly higher in mucinous tumours compared to nonmuci-
nous tumours (17.7 arbitrary units [95% CI 5.8, 30.0] vs 9.6 [5.0,
14.3] respectively, P¼0.013). Overexpression of TYMS was also
observed in both subtypes of adenocarcinoma compared to normal
mucosa. Relative to patient-matched mucosa, nonmucinous
tumours demonstrated less overexpression (tumour mean 9.6
[5.0, 14.3] vs mucosal mean 4.9 [3.5, 6.3], P¼0.01) than the
mucinous variant (tumour mean 17.7 [5.8, 30.0] vs mucosal mean
4.1 [3.2, 5.1], Po0.001). There was no difference in nonmalignant
mucosal expression of TYMS between patients with mucinous and
nonmucinous cancers.
GSTP1 expression was also significantly greater in mucinous
tumours (193.0 [108.8, 277.3]) than in nonmucinous tumours
(139.0 [72.2, 205.8], P¼0.029). Both histologic tumour subtypes
had higher expression of GSTP1 than the matched normal mucosa.
The degree of overexpression in mucinous tumours (tumour mean
193.0 [108.8, 277.3] vs mucosal mean 60.0 [39.9, 80.0], Po0.001)
was greater than in nonmucinous tumours (tumour mean 139.0
[72.2, 205.8] vs mucosal mean 51.0 [36.4, 65.6], Po0.001). There
was no difference in nonmalignant mucosal expression of GSTP1
in patients with mucinous and nonmucinous cancers.
Clinical follow-up data were available for 44 of the 51 patients
(86%); those without complete data were excluded from further
analyses. Of the 44 patients, 17 experienced recurrence. Time to
disease recurrence was evaluated for mucinous and nonmucinous
tumours. Disease-free survival between the two groups was not
significantly different, with median times to recurrence of 54.2 and
Table 2 Patient characteristics
Mucinous Nonmucinous P-value
N 21 30 —
Age (years) 68.9 69.2 0.98
Male:female 12:9 16:14 1.00
Tumour diameter (cm) 5.3 5.1 0.31
Location 0.16
Right 9 (43%) 12 (40%) —
Transverse 4 (19%) 3 (10%) —
Left/sigmoid 8 (38%) 9 (30%) —
Rectum 0 (0%) 6 (20%) —
Median no. LNs evaluated 19 16.5 0.52
Median no. positive LNs 2 2 0.78
Tumour differentiation 0.71
Poor 5 (24%) 7 (23%) —
Moderate 13 (62%) 16 (53%) —
Well 3 (14%) 7 (23%) —
All patients are stage III.
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Figure 1 Differential expression of TYMS and GSTP1 in mucinous and nonmucinous colorectal adenocarcinoma. *Po0.001 relative to patient-matched
normal mucosa;
wPo0.05 relative to nonmucinous adenocarcinoma. Error bars represent the 95% CI of the mean.
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s46.5 months (P¼0.5) for patients with mucinous and nonmuci-
nous adenocarcinoma, respectively. In all, 14 patients either did
not complete a course of primary 5-FU-based chemotherapy
(N¼8) or were treated with other first-line treatment (N¼6,
irinotecan or neoadjuvant radiation only for rectal cancer). The
median DFS for all 14 patients did not differ significantly from the
entire cohort (52 months), nor was there a detectable difference
between those with mucinous or nonmucinous tumours. However,
subset analysis of the 30 patients who received 5-FU as primary
adjuvant treatment revealed a shorter time to recurrence in
patients with mucinous tumours (Figure 2). The median DFS was
13.8 months in the population of patients with mucinous
adenocarcinoma (N¼11) who received 5-FU chemotherapy.
Conversely, patients with nonmucinous tumours (N¼19) who
underwent 5-FU treatment had a median DFS of 46.5 months; the
trend of shorter time to recurrence in these patients approached
statistical significance (P¼0.053). Among patients treated with 5-
FU, those with mucinous tumours had significantly higher TYMS
expression (mean 20.8 vs 7.4 for patients with nonmucinous
tumours who received 5-FU, P¼0.014). Owing to limited patient
numbers and clinical follow-up, subset analysis of patients
receiving other chemotherapeutic agents (i.e. oxaliplatin or
irinotecan) could not be performed. There were no differences in
recurrence or survival when patients who were treated with
adjuvant chemotherapy were stratified based on whether their
tumour expressed greater than or less than the median level of
either TYMS or GSTP1.
DISCUSSION
It is generally recognised that mucinous adenocarcinomas of the
colon and rectum have a worse prognosis following resection than
nonmucinous tumours (Symonds and Vickery, 1976; Umpleby
et al, 1985; Green et al, 1993; Consorti et al, 2000; Nozoe et al,
2000). Compared to the more common nonmucinous variety,
mucinous tumours metastasise to lymph nodes with increased
frequency (Nozoe et al, 2000), are more prone to local recurrence
(Umpleby et al, 1985; Connelly et al, 1991) and peritoneal
carcinomatosis (Nozoe et al, 2000), are less likely to be resected
with negative margins (Umpleby et al, 1985), and are typically
diagnosed at an advanced stage (Younes et al, 1993). They also
have altered p53 expression (Hanski et al, 1996) and increased
microsatellite instability (Messerini et al, 1997). Although muci-
nous tumours occur more frequently in the proximal colon, left-
sided and rectal mucinous tumours have an overall worse
prognosis relative to location-matched nonmucinous tumours
(Green et al, 1993). This finding may be at least partially explained
by over-expression of both p53 (Lenz et al, 1996) and thymidylate
synthase (Allegra et al, 2002) in left-sided tumours, although no
previous study has examined expression in the mucinous subset
alone. Based on these genetic differences and its more aggressive
clinical behaviour, some authors have suggested that mucinous
adenocarcinomas should be categorised and treated as a biological
entity distinct from other colorectal adenocarcinomas (Consorti
et al, 2000). The current study confirms the biological difference
between mucinous and nonmucinous tumours. We found
significantly higher expression of thymidylate synthase (TYMS)
and GSTP1 in mucinous colorectal adenocarcinomas than in
equivalent-stage nonmucinous tumours. Both mucinous and
nonmucinous tumours also overexpressed these genes relative to
normal colonic mucosa.
The association between high levels of TYMS in tumours and
poor clinical response following 5-FU treatment of colorectal
cancer is well documented (Johnston et al, 1995; Leichman et al,
1997; Salonga et al, 2000; Iacopetta et al, 2001). Elevated
expression has also been correlated with time to recurrence in
patients with stage II or III disease (Kornmann et al, 2002). The
finding of overexpression of TYMS in mucinous tumours in our
study offers a possible explanation as to why patients with these
tumours tend to do worse. To our knowledge, response of
mucinous tumours to 5-FU treatment has not been specifically
investigated. In the recent literature regarding mucinous adeno-
carcinoma, the large majority of patients with locally advanced
colorectal cancer would have received 5-FU. Perhaps decreased
response to 5-FU due to overexpression of TYMS contributes to
the relatively poorer prognosis for patients with mucinous
adenocarcinoma. Among patients in our study who received 5-
FU following initial surgical resection, there was a trend towards
increased DFS only in the nonmucinous tumour group. Although
the P-value did not reach the significance threshold of 0.05, this
finding intuitively makes sense, given the fact that tumours in the
nonmucinous group had significantly lower expression of TYMS.
Owing to the small number of patients who either did not complete
5-FU-based chemotherapy or received other adjuvant treatment,
no definitive conclusions can be drawn.
Oxaliplatin causes cell death by forming bulky, DNA helix-
distorting adducts via crosslinking between guanine bases. GSTP1
belongs to the glutathione S-transferase superfamily and is a major
mechanism of detoxification of platinum agents. It is highly
overexpressed in colorectal cancer, with increased levels in drug-
resistant tumours (Stoehlmacher et al, 2002). In the current study,
GSTP1 expression was found to be similarly elevated in malignant
tissue relative to normal colonic mucosa. Interestingly, expression
was significantly greater in mucinous tumours. As our cohort of
tumours was assembled in a retrospective manner from histori-
cally collected samples, none had been treated with oxaliplatin.
However, the finding of elevated GSTP1 expression within mucin-
producing tumours suggests that diminished clinical response may
be expected from oxaliplatin-treated tumours. Further research
examining this hypothesis is warranted.
Regarding the remaining ten markers, there were no significant
differences in gene expression between mucinous and nonmuci-
nous colorectal cancers. This negative finding does not imply they
do not have a role in determining outcome following chemother-
apy. Rather, they may not contribute to the differing clinical
responses seen in the treatment of mucinous adenocarcinoma
relative to the nonmucinous variant. In fact, it would be expected
that altered expression of some genes contributes to the general
drug-resistant phenotype seen in all colorectal adenocarcinomas,
while expression of others distinguishes individual biologically
distinct subtypes and determines their relative clinical respon-
siveness.
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Figure 2 Disease-free survival based on histologic subtype for all
patients who received adjuvant 5-FU (N¼30 total; P¼0.053).
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sThe intent of the current study was to examine the relative
expression in colorectal cancer of certain genes believed to
influence clinical response to adjuvant chemotherapy. It was not
designed to characterise extensively the relationships between gene
expression, response to chemotherapy, and patient outcome. The
clinical follow-up data were limited, with a median follow-up of
only 17.2 months. Since this is a retrospective study, chemotherapy
selection and dosing were not standardised. Additionally, rectal
cancers were somewhat under-represented, comprising 20% of the
nonmucinous cohort vs approximately 30% of all colorectal
adenocarcinomas. Nonetheless, several significant associations
were found that may lead to further investigations. Longer patient
follow-up and standardised treatment will be required to fully
explore the role of TYMS and GSTP1 overexpression in mucinous
adenocarcinoma. Protein analysis of these enzymes may validate
our findings and provide further insight into their complex
intracellular interactions. However, much of the data supporting
the negative influence of overexpression of both TYMS and GSTP1
on patient outcome has been generated by examining either
germline polymorphisms or transcriptional levels (Metzger et al,
1998a; Salonga et al, 2000; Stoehlmacher et al, 2002).
In addition to pharmacogenetic markers for outcome following
specific drug treatment, there are a variety of patient character-
istics (e.g. lymph node metastases, age), histologic findings (e.g.
neurovascular invasion, differentiation), and genetic factors (e.g.
p53 expression, microsatellite instability), which appear to
influence patient prognosis in colorectal cancer. We chose not to
perform an exhaustive examination of all such prognostic
factors, but instead to examine the heterogeneity and differential
expression of known pharmacogenetic markers in mucinous
adenocarcinomas. Whether other markers of prognosis such as
microsatellite instability can be utilised clinically to predict
outcome in mucinous colorectal cancer remains to be determined.
In conclusion, mucinous tumours significantly overexpressed
TYMS and GSTP1 relative to both normal mucosa and to
nonmucinous adenocarcinomas. Both these genes are known
markers for resistance to chemotherapy. Among those who
received adjuvant 5-FU, DFS was shorter in patients with
mucinous tumours. It is unclear whether the overexpression of
TYMS contributed to these earlier recurrences. Clinical response
may be improved for mucinous colorectal cancer if treated with
combination chemotherapy or perhaps agents such as irinotecan,
where no differences in drug pathway markers were identified. The
mucin status of colorectal tumours should be carefully addressed
in future trials of novel treatments.
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